'In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone.'
#immunotherapy #Immunology #immunooncology #LungCancer

https://www.nejm.org/doi/full/10.1056/NEJMoa2215530